Results will be shared at the ASCPT Annual Meeting Symposium on Saturday, March 18 (1:15 PM - 3:15 PM)

* 1. Please identify your primary sector of affiliation:

* 2. What function(s) do you represent (select all that apply)?

* 3. Is there an expectation or mandate within your organization that you will leverage prior internal/external clinical data to inform early clinical development?

* 4. Does your organization approach “knowledge capture” through models (e.g. platform models, disease models, systems models) that can be re-cycled for many projects?

* 5. Does your organization regularly review emerging internal/external data from clinical trials in cross functional setting (pre-clinical, pharmacometrics/Modeling and Simulations, biomarkers and physician-scientist) to inform clinical development strategies?

* 6. Do you apply modeling and simulation paradigms that leverage data from marketed/late stage molecules to inform development of molecules that share related mechanisms of action?

* 7. Do you apply modeling and simulation paradigms that leverage data from marketed/late stage molecules to inform development of molecules that are being developed for the same disease?

* 8. Do you encourage your discovery teams to use pertinent clinical data with an eye toward optimizing discovery of new molecular entities?

* 9. Do you use real world data e.g., electronic medical records, biobanks, registries, observational data, adverse event databases to inform development of target product profile and/ or design of clinical studies?

* 10. When presented with the term “reverse translation” what types of quantitative pharmacology activities (ideas, initiatives, studies, and analyses) do you immediately associate this with?

Report a problem

T